Your session is about to expire
← Back to Search
Monoclonal Antibodies
DSC-MRI for Recurrent Glioblastoma
N/A
Recruiting
Led By Jerrold Boxerman
Research Sponsored by ECOG-ACRIN Cancer Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients not previously treated with immunotherapies
Histologically proven intracranial glioblastoma or gliosarcoma at initial surgery
Must not have
Patient not eligible if primarily receiving bevacizumab for reasons other than tumor treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial uses DSC-MRI to measure rCBV to determine response to bevacizumab in patients with recurrent glioblastoma. DSC-MRI may help to evaluate changes in cancer blood vessels.
Who is the study for?
This trial is for adults with recurrent glioblastoma who can undergo MRI scans and have not been treated with immunotherapies. They must have a Karnofsky performance status of at least 70, no severe allergies to gadolinium, no MR-incompatible implants, and adequate organ function. Pregnant or breastfeeding women are excluded.Check my eligibility
What is being tested?
The study tests how well DSC-MRI measures blood volume changes in the brain as an early indicator of response to Bevacizumab treatment in patients experiencing their first recurrence of glioblastoma.See study design
What are the potential side effects?
While this trial focuses on imaging rather than drug effects, Bevacizumab may cause headaches, high blood pressure, bleeding problems, tiredness, and increased risk of infections.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have never received immunotherapy treatments.
Select...
My initial surgery confirmed I have glioblastoma or gliosarcoma.
Select...
I am able to care for myself but may not be able to do active work.
Select...
I can have a small needle placed in my vein for treatment.
Select...
I can safely receive IV contrast.
Select...
My kidneys work well (eGFR >= 40).
Select...
I am scheduled for treatment with a standard dose of bevacizumab.
Select...
I am not pregnant or breastfeeding.
Select...
My low-grade brain tumor has transformed into a high-grade tumor.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not taking bevacizumab for reasons unrelated to cancer treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in rCBV within enhancing tumor
OS
Secondary outcome measures
CBF
Change in CBF
PFS
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (DSC-MRI)Experimental Treatment1 Intervention
Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
2006
Completed Early Phase 1
~220
Find a Location
Who is running the clinical trial?
ECOG-ACRIN Cancer Research GroupLead Sponsor
116 Previous Clinical Trials
176,776 Total Patients Enrolled
1 Trials studying Glioblastoma
100 Patients Enrolled for Glioblastoma
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,959,255 Total Patients Enrolled
324 Trials studying Glioblastoma
23,042 Patients Enrolled for Glioblastoma
Jerrold BoxermanPrincipal InvestigatorECOG-ACRIN Cancer Research Group
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have never received immunotherapy treatments.My kidneys work well (eGFR >= 40).My weight is within the limit for an MRI scanner table.I am scheduled for treatment with a standard dose of bevacizumab.I am not taking bevacizumab for reasons unrelated to cancer treatment.My initial surgery confirmed I have glioblastoma or gliosarcoma.I am able to care for myself but may not be able to do active work.My brain tumor has grown despite treatment, and I am planned to receive bevacizumab.I can undergo MRI scans with contrast.I can have a small needle placed in my vein for treatment.I can safely receive IV contrast.I am not pregnant or breastfeeding.My low-grade brain tumor has transformed into a high-grade tumor.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (DSC-MRI)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger